NCT06093932RecruitingPhase 4
Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial
Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized, Multicenter, Double-blind, Placebo-controlled Trial
Source: ClinicalTrials.gov · Last updated 20 Aug 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is: 1. To evaluate the efficacy of Songling Xuemaikang Capsules(SLXMKC) with grade 1 hypertension. 2. To reveal the potiential effects of SLXMKC on vascular function and structure of patients with grade 1 hypertension. 3. To explore the underlying mechanisms of the therapeutic effects of SLXMKC on the intervention of grade 1 hypertension.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 17 Oct 2023
- Start date
- 7 Apr 2024
- Primary completion date
- Dec 2024
- Lead sponsor
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
- Diseases
- High blood pressure
- NCT number
- NCT06093932
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 100
- From 7 Apr 2024 to the primary completion date, Dec 2024
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Hyperlipidemia with or without taking lipid-lowering drugs;
Other illness
- Gastrointestinal diseases, which may affect drug absorption;
- Be allergic to the clinical trial medicine;
- Combined with other serious primary diseases or malignant tumors;
- Hypertensive comorbidities (cerebrovascular disease, other cardiovascular diseases, renal disease, peripheral artery disease, retinopathy, diabetes);
- Other serious conditions in which is not fit for the study.
Lab values
- Significant liver and kidney dysfunction, ALT and AST upper the twice of normal range, Scr≥2.0mg/dl, eGFR\<60ml/(min·1. 73m2);
Other
- Pregnant or breastfeeding women, men who plan to give birth within half a year;
- Combined with left ventricular hypertrophy, ABI \< 0.9, CIMT ≥ 0.9mm or atherosclerotic plaque;
Who the study is looking for
- Age between 35-65 years old, male or female;
- Grade 1 essential hypertension;
- Taking no antihypertensive drugs or taking antihypertensive drugs irregularly in the past ;
- Sign the informed consent;
Age in the registry: 35 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xiyuan Hospital of China Academy of Chinese Medical Sciences Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| Affiliated Hospital of Shandong University of Traditional Chinese Medicine Coordinator of this site? Confirm its status | Jinan | China | Not yet recruiting |
| China Academy of Chinese Medical Sciences Xiyuan Hospital Jining Hospital Coordinator of this site? Confirm its status | Jining | China | Not yet recruiting |
| Suzhou Hosptial of Traditional Chinese Medicine Coordinator of this site? Confirm its status | Suzhou | China | Not yet recruiting |
| China Academy of Chinese Medical Sciences Xiyuan Hospital Shanxi Hospital Coordinator of this site? Confirm its status | Taiyuan | China | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.